Share

    


Home / Search Results

Search Results

You searched for:

Dr. Barbara Schmidtman highlights key findings from the 2022 ACCC Mini Z burnout survey, comparing results from the pre-pandemic 2019 to now.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.
If enacted, patients with cancer across the country will benefit from increased access and new fiscal protections, including universal paid family leave.
Despite the availability of vaccines, drugs, and monoclonal antibodies, the healthcare field is more challenged than ever with the Omicron variant.